Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NKGen Biotech ( (NKGN) ) has provided an update.
On January 12, 2026, NKGen Biotech, Inc. and its affiliate NKGen Operating Biotech, Inc. amended an existing secured promissory note with AlpineBrook Capital GP I Limited, increasing available funding by an additional $295,000 and raising the total principal amount of the note to $26,135,106. The amendment also clarified the accrual of interest, specifying that interest on $25,840,106 of the principal has accrued since January 5, 2026, while interest on the new $295,000 tranche began accruing from January 12, 2026, underscoring the company’s continued reliance on debt financing to support its operations and liquidity needs.
More about NKGen Biotech
NKGen Biotech, Inc. is a biotechnology company focused on developing and commercializing cell-based therapies, particularly involving natural killer (NK) cell technologies, targeting serious diseases and unmet medical needs in the biopharmaceuticals market.
Average Trading Volume: 7,264
Technical Sentiment Signal: Sell
Current Market Cap: $7.46M
See more insights into NKGN stock on TipRanks’ Stock Analysis page.